Table 2.
S. No | Conc. (μg/mL) | % COX-2 Inhibition | IC50 μg/mL | % COX-1 Inhibition | IC50 μg/mL | % 5-LOX Inhibition |
IC50 μg/mL |
---|---|---|---|---|---|---|---|
Compound 1 | 1000 | 83.13 ± 0.80 *** | 10.70 | 66.29 ± 0.43 *** | 80.10 | 87.63 ± 0.64 ** | 7.40 |
500 | 78.83 ± 0.73 *** | 59.56±0.45 *** | 82.45 ± 0.55 *** | ||||
250 | 72.70 ± 0.51 *** | 43.54 ± 0.46 *** | 76.53 ± 0.41 *** | ||||
125 | 66.43 ± 0.70 *** | 40.57 ± 0.84 *** | 71.42 ± 0.46 *** | ||||
62.50 | 61.06 ± 0.70 *** | 22.36 ± 0.49 *** | 65.68 ± 0.64 *** | ||||
Compound 2 | 1000 | 83.17 ± 0.72 *** | 8.45 | 57.57 ±1.18 *** | 109.40 | 85.00 ± 0.30 ** | 8.71 |
500 | 78.30 ± 0.64 *** | 51.67 ± 0.11 *** | 78.76 ± 0.58 *** | ||||
250 | 73.34 ± 0.63 *** | 44.86 ± 0.02 *** | 73.67 ± 0.61 *** | ||||
125 | 68.30 ± 0.64 *** | 37.72 ± 0.45 *** | 67.74 ± 0.61 *** | ||||
62.50 | 61.93 ± 1.13 *** | 32.45 ± 0.65 *** | 63.47 ± 0.56 *** | ||||
Celecoxib | 1000 | 95.20 ± 0.15 | 3.22 | - | - | - | - |
500 | 91.17 ± 0.53 | ||||||
250 | 86.98 ± 0.85 | ||||||
125 | 81.20 ± 0.65 | ||||||
62.50 | 77.80 ± 0.37 | ||||||
Montelukast | 1000 | - | - | - | - | 93.55 ± 0.40 | 4.50 |
500 | 89.37 ± 1.65 | ||||||
250 | 85.50 ± 0.40 | ||||||
125 | 79.60 ± 0.90 | ||||||
62.50 | 74.17 ± 0.72 | ||||||
Aspirin | 1000 | - | - | 75.89 ± 0.20 | 47.08 | - | - |
500 | 71.88 ± 0.20 | ||||||
250 | 66.43 ± 0.29 | ||||||
125 | 59.84 ± 0.32 | ||||||
62.50 | 51.68 ± 0.22 |
Data are presented as (mean ± S.E.M); two-way ANOVA followed by Bonferroni test were followed. ** = p < 0.01, *** = p < 0.001.